Market Spotlight: Eating Disorders
|出版日期||內容資訊||英文 42 Pages
|焦點市場分析:飲食障礙 Market Spotlight: Eating Disorders|
|出版日期: 2019年12月02日||內容資訊: 英文 42 Pages||
This Market Spotlight report covers the Eating Disorders market, comprising key marketed and pipeline drugs, clinical trials, upcoming events, patent information, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
Worldwide, Datamonitor Healthcare estimates that in 2017, there were approximately 35.6 million prevalent cases of eating disorders in females aged 10-19 years, including 3.0 million cases of anorexia nervosa, 11.6 million cases of bulimia nervosa, and 14.3 million cases of binge eating disorder.
In this demographic group, Datamonitor Healthcare forecasts the number of prevalent cases of eating disorders to increase to 38.1 million by
2026. Edgemont's fluoxetine tablets, Eli Lilly's Prozac, and Takeda's Vyvanse are the only FDA-approved drugs for eating disorders. These drugs are administered via the oral route, with Vyvanse also available in an intranasal formulation.
There are only two industry-sponsored drugs in active clinical development for eating disorders, with one drug each in Phase II and the NDA/BLA phase.
Therapies in development for eating disorders focus on targets such as dopamine reuptake, norepinephrine (noradrenaline) reuptake/transporter, and ghrelin receptor. These drugs are administered via the oral and subcutaneous routes.
The only high-impact upcoming event in the eating disorders space is an expected PDUFA date for dasotraline. The overall likelihood of approval of a Phase I psychiatry-other asset is 10.8%, and the average probability a drug advances from Phase III is 78.6%. Drugs, on average, take 9.3 years from Phase I to approval, compared to 8.9 years in the overall psychiatry space.
There have been only three licensing and asset acquisition deals involving eating disorders drugs during 2014-19. The values were not disclosed for any of these deals.
All of the clinical trials for eating disorders have been in Phase III.
The US leads in terms of the number of eating disorders clinical trials globally, while Germany leads the major EU markets. Clinical trial activity in the eating disorders space consists entirely of completed trials. Takeda has the highest number of completed clinical trials for eating disorders, with three trials.
Takeda leads industry sponsors with the highest number of overall clinical trials for eating disorders, followed by Johnson & Johnson.
25 Relamorelin for Eating Disorders (June 25, 2019)
26 OPNT001 for Eating Disorders (February 21, 2019)
27 Dasotraline for Eating Disorders (July 25, 2018)
36 Sponsors by status
37 Sponsors by phase
39 Prescription information